Navigation Links
Singapore scientists lead human embryonic stem cell study
Date:11/28/2011

Researchers from A*STAR Singapore took lead roles in a study that identified a portion of the genome mutated during long-term culture of human embryonic stem cells (hESCs). The study was a worldwide collaboration, led by Drs Peter Andrews of the University of Sheffield (UK), Paul Robson of the Genome Institute of Singapore (GIS), Steve Oh of Singapore's Bioprocessing Technology Institute (BTI), and Barbara Knowles and others in the international stem cell community. The GIS, IMB and BTI are research institutes under the umbrella of the Agency for Science, Technology and Research, (A*STAR), Singapore.

Involving 125 ethnically diverse hESC lines originating from 38 laboratories globally, and now identified to represent multiple ethnic groups from different parts of the globe, the study is the largest to be conducted on the genetic stability of cultured hESCs. The findings are published today in the journal Nature Biotechnology.

Research into the variability of hESCs is very important as these cells may lead to future cell therapy and regenerative medicine. During long-term culture, however, these cells can acquire genetic changes (mutations), some of which could compromise the cells' utility for regenerative medicine. It is believed that mutations that arise and endure over long-term culture provide a selective advantage for the cells, such as a greater propensity for self renewal.

The study re-emphasized that many chromosome changes occur repeatedly, resulting in increased copies in specific areas of the genome. Interestingly, through molecular karyotyping performed in Dr Robson's laboratory at the GIS, about 20% of the karyotypically normal cell lines exhibited subkaryotypic amplifications of a specific region in chromosome 20. This is also one of the karyotypically defined areas of change. The minimal region common to these cells contains three ES-cell expressed genes, and one of them, BCL2L1, is a strong candidate for drivi
'/>"/>

Contact: Winnie Serah Lim
limcp2@gis.a-star.edu.sg
65-680-88013
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Singapore to hold international pow-wow
2. Singapore Medicine - Breakthrough Development of Cell Therapy Treatment for Cancer
3. Singapore Medicine - Singapore Doctors Use Hi-Tech Implant to Add Space to Narrowed Spinal Canals
4. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
5. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
6. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
7. PAREXEL Receives BioSingapore Award for Best Performing CRO
8. Moleac Named Singapore Entrepreneurial Company of the Year at the Frost & Sullivan Excellence in Healthcare Awards
9. Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore
10. Pharma and Biotech Companies Plug into Singapores Integrated Research Network
11. ICON Central Laboratories in Singapore Moves to New Facility to Meet Growing Demand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is pleased to announce that its wholly owned ... lead candidate, PPL-003, to an Investigational New Drug (IND) ... and uveitis.  PPL recently completed a study in a ... solution achieved highly significant efficacy and a more rapid ...
(Date:8/31/2015)... SHANGHAI , Aug. 31, 2015 /PRNewswire/ ... next-generation antibiotics, today announced positive top-line results from ... lead drug candidate MRX-I. MRX-I is an oral ... as MRSA and VRE, while offering physicians and ... than currently available oxazolidinone agents. ...
(Date:8/31/2015)... -- Trimb Healthcare AB ("Trimb") today announced that it ... ("YouMedical"), a Dutch OTC company with operations in key ... EUR 16 million, with solid growth and leading brands ... to build a leading international OTC company, and this ... gives us a stronger North European OTC platform, from ...
(Date:8/31/2015)... ... 31, 2015 , ... There’s a new treatment option for excessive menstrual bleeding ... new FDA approved system in the last 14 years, and the only endometrial ablation ... bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and the fastest ...
Breaking Biology Technology:Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... July 21, 2011 The U.S. Food & Drug ... a clinical trial for gene therapy for a rare ... and London, this trial based on preclinical research performed ... gene therapy product, is now going to be launched ...
... July 21, 2011 Advanced Cell Technology, Inc. ("ACT"; ... medicine, announced today that it has entered into an ... Biotech"), a leading South Korea-based biotechnology company, designed to ... venture, Stem Cell & Regenerative Medicine International (SCRMI).  Under ...
... DURHAM, N.C. Researchers at Duke University Medical Center ... of Chlamydia , the bacteria responsible for the ... States. The team, which included Duke University ... the bacteria,s self-defense mechanisms. The therapies that ...
Cached Biology Technology:Genethon and Children's Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial 2Genethon and Children's Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial 3Genethon and Children's Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial 4Genethon and Children's Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial 5ACT Obtains Exclusive License for Hemangioblast Technology in North America 2ACT Obtains Exclusive License for Hemangioblast Technology in North America 3ACT Obtains Exclusive License for Hemangioblast Technology in North America 4ACT Obtains Exclusive License for Hemangioblast Technology in North America 5Newly designed molecule blocks chlamydia bacteria 2Newly designed molecule blocks chlamydia bacteria 3
(Date:8/28/2015)... -- According to a new market research ... (Pen & Paper Based, Hosted, Biometrics), Service, Application (Clinical ... Vertical and Region - Global Forecast to 2020", published ... from USD 2.4 Billion in 2015 to USD 7.5 ... (CAGR) of 25.6% from 2015 to 2020. ...
(Date:8/24/2015)... August 24, 2015 The consulting company ... largest biometrics manufacturer DERMALOG and its customized solutions and products ... Biometrics Company of the Year Award". DERMALOG is particularly successful ... .   -Cross reference: Picture is available at ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... 20, 2015   Sensory, Inc ., a ... user experience and security of consumer electronics through ... that its TrulySecure™ is the first ... be FIDO Certified™. The FIDO (Fast ... the FIDO UAF (Universal Authentication Framework) 1.0 specifications, ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
... STATION Researchers at Texas A&M University have confirmed for ... off the Texas coast for at least the past 23 ... to marine life in the area. Steve DiMarco, associate ... dead zones in the Gulf of Mexico for more than ...
... fresh evidence that urbanization in the United States threatens the ... six-year study also refutes one of the most widely accepted ... kinds of birds. Most ecologists have assumed that common ... and raccoons were destroying eggs or killing young birds ...
... Md., April 1, 2008 The U.S. Pharmacopeial (USP) ... dissolution variability of USP Prednisone Lot P Reference Standard ... less variability in USP Prednisone Lot P tablets than ... dosage forms plays a critical role in drug manufacturing ...
Cached Biology News:Researchers confirm dead zone off Texas coast since 1985 2Some migratory birds can't find success in urban areas, study finds 2Some migratory birds can't find success in urban areas, study finds 3Prednisone tablets less variable than marketed drugs 2
Homo sapiens 4-aminobutyrate aminotransferase Antigen: Recombinant Protein...
... Serum • Mouse serum is collected off the clot ... weeks of age. Available Anticoagulants: N-02: ... K2EDTA N-08: Potassium Oxalate N-10: ... ACD N-07: CPD N-09: ...
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
RABBIT ANTI HUMAN TRRAP (CT) Immunogen: Recombinant C-terminal kinase-related domain of human TRRAP....
Biology Products: